Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2012
05/17/2012US20120122771 STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN
05/17/2012US20120122765 Compounds and related methods for manipulating parp-1-dependent cell death
05/17/2012US20120122764 Substituted carbamoylcycloalkyl acetic acid derivatives as nep
05/17/2012US20120122763 Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
05/17/2012US20120122762 186 Human Secreted Proteins
05/17/2012US20120122204 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
05/17/2012US20120122109 Neural progenitor cells derived from embryonic stem cells
05/17/2012US20120121729 Antitussive compositions comprising memantine
05/17/2012US20120121724 Film comprising therapeutic agents
05/17/2012US20120121721 Skin care products and compositions
05/17/2012US20120121720 Modulation of Beta 2 Adrenergic Receptors by Inhibitors of EGLN3 or pVHL
05/17/2012US20120121719 Methods of making and using three-dimensional extracellular matrices
05/17/2012US20120121711 Microsphere drug carrier, preparation method, composition and use thereof
05/17/2012US20120121708 Acetazolamide Microparticle And Its Preparation Method And Use
05/17/2012US20120121701 Pharmaceutical composition of peptide drug and enzyme-inhibition compounds
05/17/2012US20120121698 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
05/17/2012US20120121668 Compositions for oral adminstration of active principles requiring masking of taste
05/17/2012US20120121667 Pharmaceutical Composition
05/17/2012US20120121656 Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease
05/17/2012US20120121640 OX40/TRAIL Fusion Proteins
05/17/2012US20120121619 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
05/17/2012US20120121606 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
05/17/2012US20120121601 Mammalian receptor proteins; related reagents and methods
05/17/2012US20120121591 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
05/17/2012US20120121585 SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
05/17/2012US20120121584 Monoclonal Antibodies Against Extracellular Loops of C5aR
05/17/2012US20120121583 Antibodies against human tweak and uses thereof
05/17/2012US20120121581 Anti-Botulism Antibody Coformulations
05/17/2012US20120121578 Methods of using immunoglobulin aggregates
05/17/2012US20120121562 Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
05/17/2012US20120121559 Treatment and prevention of pathological conditions using iduna related techniques and compositions
05/17/2012US20120121556 Methods of using regenerative cells to promote wound healing
05/17/2012US20120121554 Hmg-coa secondary metabolites and uses thereof
05/17/2012US20120121550 Production of oligodendrocytes from placenta-derived stem cells
05/17/2012US20120121542 Red-shifted opsin molecules and uses thereof
05/17/2012US20120121541 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
05/17/2012US20120121530 Vasoprotective and cardioprotective antidiabetic therapy
05/17/2012US20120121520 Functional formulation in chewing gum
05/17/2012US20120121508 Radiolabeled cgrp antagonists
05/17/2012US20120121502 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
05/16/2012EP2453010A1 Neural progenitor cells derived from embryonic stem cells
05/16/2012EP2453009A1 Methods of organ regeneration
05/16/2012EP2452690A1 Carboxymethylarginine production inhibitor and collagen denaturation inhibitor
05/16/2012EP2452683A2 Methods for treating atherosclerosis
05/16/2012EP2451815A1 INDUCTION OF alpha-HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES
05/16/2012EP2451813A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
05/16/2012EP2451807A1 Cyclic triazo sodium channel blockers
05/16/2012EP2451779A2 Etomidate analogues that do not inhibit adrenocortical steroid synthesis
05/16/2012EP2451771A1 Salts of rasagiline and pharmaceutical preparations thereof
05/16/2012EP2451456A1 Combined preparation for use as a medicament
05/16/2012EP2451455A2 Rxr agonist compounds and methods
05/16/2012EP2451449A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
05/16/2012EP2313413B1 Pyrazolo [1, 5-a] pyrimidine derivatives
05/16/2012EP2305645B1 Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
05/16/2012EP2268628B1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
05/16/2012EP2183247B1 New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl]1h- indole- 5 -carbonitrile citrate
05/16/2012EP2135951B1 Method of preparing human NGF Beta protein
05/16/2012EP2131837B1 Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
05/16/2012EP1997486B1 Therapeutic agent for functional brain disease
05/16/2012EP1480993B2 Desaturase genes, enzymes encoded thereby, and uses thereof
05/16/2012CN1968697B Neuroprotective properties of dextrorotatory morphinans
05/16/2012CN102460175A STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN
05/16/2012CN102459348A 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 Fusion protein is used to gdnf and bdnf delivered to the central nervous system
05/16/2012CN102459337A Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
05/16/2012CN102459336A Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
05/16/2012CN102459335A 特异性结合Aβ寡聚体的抗体及其用途 Aβ oligomer-specific binding antibodies and uses thereof
05/16/2012CN102459313A High penetration prodrug compositions of peptides and peptide-related compounds
05/16/2012CN102459291A 神经保护性化合物和它们的应用 Neuroprotective compounds and their applications
05/16/2012CN102459279A 治疗剂713 Therapeutic agent 713
05/16/2012CN102459272A 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法 Selective for P110δ bicyclic pyrimidine compounds and methods of use for the PI3K inhibitor
05/16/2012CN102459268A Diazahomoadamantane derivatives and methods of use thereof
05/16/2012CN102459255A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459252A 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶 For the treatment of glycogen synthase kinase 3-related diseases such as Alzheimer's disease pyrimidine substituted imidazole
05/16/2012CN102459247A 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物 As aldosterone synthase inhibitors benzoxazole derivatives
05/16/2012CN102459244A 喹唑啉二酮衍生物、其制备及其多种治疗用途 Quinazoline dione derivatives, their preparation and their therapeutic uses multiple
05/16/2012CN102459242A Phenoxymethyl heterocyclic compounds
05/16/2012CN102459240A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459232A 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
05/16/2012CN102459230A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459229A 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 Orexin antagonists used azabicyclo [4.1.0] heptane
05/16/2012CN102459228A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459221A 噻吩衍生物 Thiophene derivative
05/16/2012CN102459210A Arylsulfonamide ccr3 antagonists
05/16/2012CN102459200A 适用于治疗响应于调节血清素5-ht6受体的疾病的苯磺酰基苯胺化合物 Applicable to the treatment response to serotonin 5-ht6 regulating receptor diseases Phenylsulfonylaniline compound
05/16/2012CN102459198A Crystals
05/16/2012CN102459197A 适用于治疗响应血清素5-HT<sub>6</sub>受体的调节的病症的N-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物 Applicable to the treatment response serotonin 5-HT <sub> 6 </ sub> receptor modulated disorders of N- phenyl - (piperazinyl or homopiperazinyl) - benzenesulfonamide or benzenesulfonyl - phenyl - (piperazine or homopiperazine) compound
05/16/2012CN102459189A 5-元杂环化合物环戊二烯并[c]吡咯基烷基氨基甲酸酯衍生物、其制备、及其治疗用途 5-membered heterocyclic compound cyclopenta [c] pyrrolyl group carbamate derivatives, their preparation, and their therapeutic use
05/16/2012CN102459185A 新型甲状腺激素β受体激动剂 Novel thyroid hormone receptor β agonists
05/16/2012CN102459178A 2,5-disubstituted arylsulfonamide ccr3 antagonists
05/16/2012CN102459177A 2,5-disubstituted arylsulfonamide ccr3 antagonists
05/16/2012CN102459172A 四环化合物 Tetracyclic compounds
05/16/2012CN102459167A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459166A Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2012CN102459158A 新的酰胺和脒衍生物和其用途 Novel amide and amidine derivatives and use thereof
05/16/2012CN102458478A Albumin-amyloid peptide conjugates and uses thereof
05/16/2012CN102458476A 用于治疗多发性硬化症的组合物及方法 Treatment of multiple sclerosis compositions and methods for
05/16/2012CN102458454A 用于治疗亨廷顿病的组织激肽释放酶 Tissue bradykinin release for the treatment of Huntington's disease enzyme
05/16/2012CN102458453A 用于治疗精神分裂症和双相型障碍的组织激肽释放酶 Tissue for the treatment of schizophrenia and bipolar disorder kallikrein
05/16/2012CN102458450A Lactoferrin and brain health and development in infants
05/16/2012CN102458448A Lactoferrin and brain health and protection in adults
1 ... 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 ... 1833